# Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

> **NCT00953771** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 9 (actual)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Danazol

## Key facts

- **NCT ID:** NCT00953771
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2015-11-19
- **Final completion:** 2015-11-19
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2024-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00953771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00953771, "Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00953771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*